PURPOSE: The purpose of this study was to examine gender- and age-specific prevalence, incidence, and the type of anti-asthma medications used in the Norwegian population aged 2-29 years during 2005-2007 and to estimate the share of individuals who regularly redeemed medications over a 3-year period. METHODS: We retrieved data from the nationwide Norwegian Prescription Database for all individuals 2-29 years old (n = 1.7 million) who received anti-asthma medications during 2005-2007. Medications included inhaled short- and long-acting beta(2)-agonists, inhaled corticosteroids, fixed-dose combinations of inhaled beta(2)-agonists and corticosteroids, and leukotriene antagonists. RESULTS: In 2007, 5.5% (92,074 individuals) of Norwegians aged 2-29 years received anti-asthma medication, and this figure was stable throughout 2005-2007. Prevalence and incidence were higher among males than females but shifted to female dominance during adolescence. The share of anti-asthma medication users who received inhaled corticosteroids was high in preschool children but decreased by age. Conversely, use of inhaled beta(2)-agonists as monotherapy and of fixed combinations increased with age. Fewer than half the individuals were "persistent" to medication treatment for 3 years by redeeming prescriptions regularly (at least once a year). CONCLUSIONS: In this nationwide study, annual prevalence of anti-asthma medication use was stable during 2005-2007. The gender- and age-specific profile of prevalence and incidence correspond well with other studies. Fewer than half the individuals redeemed prescriptions regularly over 3 years.
PURPOSE: The purpose of this study was to examine gender- and age-specific prevalence, incidence, and the type of anti-asthma medications used in the Norwegian population aged 2-29 years during 2005-2007 and to estimate the share of individuals who regularly redeemed medications over a 3-year period. METHODS: We retrieved data from the nationwide Norwegian Prescription Database for all individuals 2-29 years old (n = 1.7 million) who received anti-asthma medications during 2005-2007. Medications included inhaled short- and long-acting beta(2)-agonists, inhaled corticosteroids, fixed-dose combinations of inhaled beta(2)-agonists and corticosteroids, and leukotriene antagonists. RESULTS: In 2007, 5.5% (92,074 individuals) of Norwegians aged 2-29 years received anti-asthma medication, and this figure was stable throughout 2005-2007. Prevalence and incidence were higher among males than females but shifted to female dominance during adolescence. The share of anti-asthma medication users who received inhaled corticosteroids was high in preschool children but decreased by age. Conversely, use of inhaled beta(2)-agonists as monotherapy and of fixed combinations increased with age. Fewer than half the individuals were "persistent" to medication treatment for 3 years by redeeming prescriptions regularly (at least once a year). CONCLUSIONS: In this nationwide study, annual prevalence of anti-asthma medication use was stable during 2005-2007. The gender- and age-specific profile of prevalence and incidence correspond well with other studies. Fewer than half the individuals redeemed prescriptions regularly over 3 years.
Authors: K C Lødrup Carlsen; G Håland; C S Devulapalli; M Munthe-Kaas; M Pettersen; B Granum; M Løvik; K-H Carlsen Journal: Allergy Date: 2006-04 Impact factor: 13.146
Authors: Christine L Parr; Maria C Magnus; Øystein Karlstad; Margaretha Haugen; Helga Refsum; Per M Ueland; Adrian McCann; Per Nafstad; Siri E Håberg; Wenche Nystad; Stephanie J London Journal: Am J Respir Crit Care Med Date: 2017-01-15 Impact factor: 21.405
Authors: Steve W Turner; Kathryn Richardson; Annie Burden; Mike Thomas; Clare Murray; David Price Journal: NPJ Prim Care Respir Med Date: 2015-06-11 Impact factor: 2.871
Authors: Maria C Magnus; Rosalind J Wright; Espen Røysamb; Christine L Parr; Øystein Karlstad; Christian M Page; Per Nafstad; Siri E Håberg; Stephanie J London; Wenche Nystad Journal: Am J Epidemiol Date: 2018-06-01 Impact factor: 4.897
Authors: Osemeke U Osokogu; Alexandra Pacurariu; Mees Mosseveld; Peter Rijnbeek; Daniel Weibel; Katia Verhamme; Miriam C J M Sturkenboom Journal: Pharmacoepidemiol Drug Saf Date: 2018-04-24 Impact factor: 2.890